First Treatment for MPS IVA Approved
BioMarin Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Vimizim™ (elosulfase alfa), the first specific therapy approved for the treatment of Morquio A (MPS IVA syndrome.)
40 Years of Achievements Gala Invitation
The National MPS Society cordially invites you to join us in celebrating 40 years of achievements through honoring the heroes of MPS research, innovation, advocacy, and courage.
27th Annual Family Conference Photos!
Thank you to everyone that attended our 27th Annual Family Conference in San Antonio, TX. Photos from the conference are available on our Facebook page.
Family Support Programs
Are you an active member of the National MPS Society and need assistance from our Family Support Programs? Learn more about how you can apply for one of our programs online!
Mucopolysaccharidoses (MPS) and related diseases are genetic lysosomal storage diseases (LSD) caused by the body's inability to produce specific enzymes. Normally, the body uses enzymes to break down and recycle materials in cells. In individuals with MPS and related diseases, the missing or insufficient enzyme prevents the proper recycling process, resulting in the storage of materials in virtually every cell of the body.